Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers

被引：0

作者：

Ikeda, S. ^{[1
]}

Muto, M. ^{[2
]}

Sato, T. ^{[3
]}

Lee, M. ^{[4
]}

Olsen, S. ^{[5
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[2] Kyoto Univ Hosp, Dept Therapeut Oncol, Kyoto, Japan

[3] Utsunomiya Cent Clin, Oncol, Utsunomiya, Tochigi, Japan

[4] Guardant Hlth Pte Ltd, Med Affairs, Singapore, Singapore

[5] Guardant Hlth Pte Ltd, Med & Clin Affairs Dept, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.304

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

310P

引用

页码：S1363 / S1363

页数：1

共 30 条

[21] Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
Armstrong, A. J.
Saad, F.
Thiery-Vuillemin, A.
Oya, M.
Shore, N. D.
Mehra, N.
Ozguroglu, M.
Gedye, C.
Sartor, O.
Poehlein, C. H.
Qiu, P.
Liu, Y-Z.
Riva, L.
Harrington, L.
Barker, L.
Del Rosario, P. M. D.
Barnicle, A.
Clarke, N.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1168 - S1168
[22] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Sieber, O.
Prasse, D.
Lamik, A.
Fredebohm, J.
Simes, J.
Day, F.
Jeffery, M.
Zielinski, R.
Singh, M.
Chong, G.
Li, S.
Mouradov, D.
Chia, J.
Ali, R.
Toh, H.
Jones, F.
Segelov, E.
ANNALS OF ONCOLOGY, 2022, 33 : S282 - S283
[23] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, Daphne
Starus, Anna
Sieber, Oliver
Prasse, Daniela
Lamik, Agathe
Fredebohm, Johannes
Simes, John
Day, Fiona
Jeffery, Mark
Zielinski, Robert
Singh, Madhu
Chong, Geoffrey
Shan, Li
Mouradov, Dmitri
Chia, John W. K.
Ali, Raghib
Toh, Han Chong
Jones, Frederick
Segelov, Eva
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 120 - 121
[24] Detection of clinically relevant early genomic lesions in B-cell malignancies from circulating tumour DNA using a single hybridisation-based next generation sequencing assay
Blombery, Piers A.
Ryland, Georgina L.
Markham, John
Guinto, Jerick
Wall, Meaghan
McBean, Michelle
Jones, Kate
Thompson, Ella R.
Cameron, Daniel L.
Papenfuss, Anthony T.
Prince, Miles H.
Dickinson, Michael
Westerman, David Alan
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 146 - 149
[25] IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study.
Aguado, Elia
Abou-Alfa, Ghassan K.
Zhu, Andrew X.
Macarulla, Teresa
Fan, Bin
Nejad, Parham
Choe, Sung
Jiang, Liewen
Gliser, Camelia
Pandya, Shuchi Sumant
Wu, Bin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR-mutant lung adenocarcinoma
Goldberg, Sarah B.
Narayan, Azeet
Carriero, Nicholas J.
Nemati, Roxanne
Bommakanti, Ananth
Wurtz, Anna
Boffa, Daniel J.
Decker, Roy H.
Herbst, Roy S.
Juergensmeier, Juliane M.
Politi, Katerina A.
Gettinger, Scott N.
Patel, Abhijit
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.
Isaacs, James
Nixon, Andrew B.
Bolch, Emily
Quinn, Katie
Banks, Kimberly
Hanks, Brent Allen
Strickler, John H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[28] KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation
Lastraioli, Elena
Antonuzzo, Lorenzo
Fantechi, Beatrice
Di Cerbo, Luisa
Di Costanzo, Alessandro
Lavacchi, Daniele
Armenio, Miriam
Arcangeli, Annarosa
Castiglione, Francesca
Messerini, Luca
Di Costanzo, Francesco
ONCOLOGY LETTERS, 2021, 21 (01)
[29] Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
Slater, Susanna
Bryant, Annette
Aresu, Maria
Begum, Ruwaida
Chen, Hsiang-Chi
Peckitt, Clare
Lazaro-Alcausi, Retchel
Carter, Paul
Anandappa, Gayathri
Khakoo, Shelize
Branagan, Graham
George, Nicol
Abulafi, Muti
Duff, Sarah
West, Nicholas
Bucheit, Leslie
Rich, Thereasa A.
Chau, Ian
Starling, Naureen
Cunningham, David
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 169 - 169
[30] Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Kawamoto, Y.
Nakamura, Y.
Ikeda, M.
Bando, H.
Esaki, T.
Ueno, M.
Nishina, T.
Kagawa, Y.
Oki, E.
Denda, T.
Mizukami, T.
Takahashi, N.
Okano, N.
Miki, I.
Sakamoto, Y.
Lefterova, M. I.
Odegaard, J. I.
Taniguchi, H.
Morizane, C.
Yoshino, T.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 →